Skip to main content
Ayan Mukherjee

Ayan Mukherjee

Director of Biostatistics at Eli Lilly, specializing in Project Optimus and dose optimization in oncology clinical trials.

Jul 21, 2026

3:02
Maybe you can introduce us a little bit to what that is and where that was coming from.
3:08
Right.
3:08
First of all, thanks for asking this question.
3:10
It's a very important topic, and it's been discussed worldwide in various different ways.
3:17
So I will try to briefly summarize of what the overall background is and what the current trend is in terms of thought process on this topic.
3:28
So traditionally, when cancers were treated with chemotherapies, the way the chemotherapy works is that it directly goes and burns the tumor cells, and that's why as the doses were increased, the toxicity used to increase due to the medication as well as the efficacy used to increase because more tumor cells were getting burnt.
3:54
And therefore, mathematically, the assumption of efficacy and toxicity increasing monotonically with increase in dose was valid for traditional chemotherapy medication.

16 MINS LATER

19:55
What tools or documents that are available that make it easier for teams to introduce these kind of designs?

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.